Premium
Upfront use of gemtuzumab ozogamicin in young children with CD33‐positive AML
Author(s) -
Sayar Dror,
Burstein Yoav,
Bielorai Bela,
Toren Amos,
Dvir Rina
Publication year - 2010
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22404
Subject(s) - gemtuzumab ozogamicin , medicine , cd33 , toddler , myeloid leukemia , complete remission , chemotherapy , pediatrics , oncology , cd34 , stem cell , psychology , developmental psychology , genetics , biology
Gemtuzumab ozogamicin (GO) is a humanized anti‐CD33 antibody used for treating patients with CD33+ acute myeloid leukemia (AML). We report three young children (two infants and one toddler) with AML treated with GO 9 mg/m 2 . Two received two doses at diagnosis alone with conventional chemotherapy and one received one dose after relapse. GO was well tolerated and all three achieved remission. All were transplanted: one relapsed after 5 months and died of disease, one died a toxic death in remission due to pulmonary fibrosis, and one survived (41 months from diagnosis). In conclusion, GO was well tolerated in these young patients with evidence for efficacy. Pediatr Blood Cancer 2010;55:183–185. © 2010 Wiley‐Liss, Inc.